Cumberland Pharmaceuticals (CPIX) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 108.7% versus a loss of 67.6%. Over five years, CPIX leads with a +167.9% price change compared with -100.0% for TNXP. Cumberland Pharmaceuticals is the larger company by market cap ($107.6 million vs $103.6 million), about 1.0 times the size, while Tonix Pharmaceuticals is growing revenue faster (+29.8% vs +17.6%).
Cumberland Pharmaceuticals converts more of its revenue into profit, with a net margin of -6.4% versus -946.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | TNXP |
|---|---|---|
| Share price | $7.18 | $6.04 |
| Market cap | $107.58M | $103.59M |
| 1-day change | -4.77% | -5.92% |
| YTD return | +80.40% | -61.33% |
| 1-year return | +108.72% | -67.56% |
| 5-year return | +167.91% | -100.00% |
| Forward P/E | 51.29 | — |
| EPS (TTM) | $-0.62 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $13.11M |
| Revenue growth (YoY) | +17.57% | +29.85% |
| Net income (latest FY) | $-2.84M | $-124.02M |
| Gross margin | 85.02% | 49.34% |
| Operating margin | -6.27% | -959.05% |
| Net margin | -6.37% | -946.22% |
| 52-week high | $9.28 | $20.58 |
| 52-week low | $1.85 | $6.01 |
| Distance from 52-week high | -22.63% | -70.65% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +636.75% |
| Average volume | 76.95K | 607.68K |
| Shares outstanding | 14.98M | 17.15M |
| Employees | 88 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed TNXP by 176.3 percentage points over the past year.
- Cumberland Pharmaceuticals is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -946.2 cents for Tonix Pharmaceuticals.
- Tonix Pharmaceuticals grew revenue faster in its latest fiscal year (+29.85% vs +17.57%).
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
CPIX vs TNXP FAQ
Which is bigger, Cumberland Pharmaceuticals or Tonix Pharmaceuticals?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $107.58M compared with $103.59M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, CPIX or TNXP?
CPIX returned +108.72% over the past 12 months, compared with -67.56% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.